LoginSignup
MorphoSys logo

MorphoSys Stock

StockStock
ISIN: DE0006632003
Ticker: MOR
DE0006632003
MOR

Price

Frequently asked questions

What is MorphoSys's market capitalization?

The market capitalization of MorphoSys is $2.70B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for MorphoSys?

MorphoSys's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$13.28. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for MorphoSys's stock?

Currently, 11 analysts cover MorphoSys's stock, with a consensus target price of $59.08. Analyst ratings provide insights into the stock's expected performance.

What is MorphoSys's revenue over the trailing twelve months?

Over the trailing twelve months, MorphoSys reported a revenue of $195.14M.

What is the EBITDA for MorphoSys?

MorphoSys's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$548.68M. EBITDA measures the company's overall financial performance.

What is the free cash flow of MorphoSys?

MorphoSys has a free cash flow of -$320.61M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of MorphoSys's stock?

The 5-year beta for MorphoSys is 0.73. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does MorphoSys have, and what sector and industry does it belong to?

MorphoSys employs approximately 446 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of MorphoSys's shares?

The free float of MorphoSys is 1.07M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $2.70B

5Y beta

 0.73

EPS (TTM)

 -$13.28

Free Float

 1.07M

Revenue (TTM)

 $195.14M

EBITDA (TTM)

 -$548.68M

Free Cashflow (TTM)

 -$320.61M

Pricing

52W span
$20.15$73.27

Analyst Ratings

The price target is $59.08 and the stock is covered by 11 analysts.

Buy

4

Hold

7

Sell

0

Information

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

446

Biotechnology & Drugs

Health Care

Identifier

ISIN

DE0006632003

Primary Ticker

MOR
Join the conversation
Sign upLogin